Treatment of oropharyngeal cancer during the COVID-19 lockdown — outcomes for patients treated during the pandemic
Abstract
Background: The onset of the coronavirus disease 2019 (COVID-19) outbreak caused major interruptions to the entire healthcare network affecting referral, diagnosis and treatment pathways with the potential to affect cancer treatment outcomes. In Ireland a national lockdown was initiated in March 2020 involving a stay-at-home order with a limitation on travel, social interactions and closure of schools, universities and childcare facilities. We designed a retrospective study comparing treatment outcomes for patients with oropharyngeal cancer treated before and during the COVID pandemic.
Materials and methods: All patients receiving radical radiotherapy for oropharyngeal cancer pre-COVID (July 17 – July 18) and during COVID (Mar 20 – Mar 21) were included. Patient and disease characteristics, diagnostic timelines, treatment delays and disease outcomes were extracted from the patient record. Disease free survival and overall survival were calculated for both groups.
Results: 159 oropharynx patients were included, 76 in the pre-COVID group (Group 1) and 83 in the pandemic group (Group 2). When comparing Group 1 and 2, respectively:
There were no differences in human papilloma virus (HPV) status (74% vs. 71% p = 0.795) or Tumour–Node–Metastasis (TNM) overall stage [American Joint Committee on Cancer (AJCC) ed. 8]: (Stage 1: 25% vs. 45.8%, Stage 2: 28.9% vs. 18.1%, Stage 3: 21% vs. 15.7%, Stage 4: 25% vs. 20.5%, p = 0.268). Use of moderate hypofractionated regime increased during the pandemic (2.6% to 10.8%) and one patient omitted chemotherapy due to COVID related reasons. There was no change in overall treatment times between groups with COVID related sepsis accounting for one significant delay and one death during treatment.
Overall survival at 2 years via Kaplan-Meier analysis; Group 1 cumulative proportion surviving at 2 years was 77% [95% confidence interval (CI): 67–86%] vs. 85% in Group 2 (95% CI: 77–93%, p = 0.35). The disease free survival at 2 years was 69% in Group 1 (95% CI: 59–80%) vs. 76% in Group 2 (95% CI: 67–85%, p = 0.567).
Conclusion: In spite of challenges related to the COVID-19 pandemic, we have demonstrated that oropharyngeal cancer patients treatment standards and outcomes were maintained. We did not demonstrate any significant difference in overall survival and disease free survival at 2 years when compared to a similar group prior to the pandemic.
Keywords: COVID-19head and neck cancerradiotherapy
References
- Ireland NPHET Dept. of Health. Statement from the National Public Health Emergency Team - Thursday 12 March. 2020 Mar. https://www.gov.ie/en/press-release/ef869a-statement-from-the-national-public-health-emergency-team/.
- O'Reilly S, Kathryn Carroll H, Murray D, et al. Impact of the COVID-19 pandemic on cancer care in Ireland - Perspectives from a COVID-19 and Cancer Working Group. J Cancer Policy. 2023; 36: 100414.
- Drake I, Rogers A, Stewart M, et al. The impact of coronavirus disease 2019 on the head and neck cancer pathway in the West of Scotland. J Laryngol Otol. 2022; 136(6): 535–539.
- Ireland National Cancer Control Programme. NCCP advise on the management of patients undergoing radiation oncology treatment, in response to the current novel coronavirus COVID-19 pandemic (CD19-100-008/ 06.12.21). 2020. https://hli.ie/c.php?g=679077&p=4900461.
- Kang JJ, Wu Y, Rybkin A, et al. Oropharyngeal Cancer Early Outcomes and Challenges During the COVID-19 Pandemic. Int J Radiat Oncol Biol Phys. 2021; 111(3): e412.
- Venkatasai J, John C, Kondavetti SS, et al. Impact of COVID-19 Pandemic on Patterns of Care and Outcome of Head and Neck Cancer: Real-World Experience From a Tertiary Care Cancer Center in India. JCO Glob Oncol. 2022; 8: e2100339.
- Schoonbeek RC, de Jel DVC, van Dijk BAC, et al. Dutch Head, Neck Society, the COVID, Cancer-NL consortium. Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: A nationwide population-based analysis. Radiother Oncol. 2022; 167: 42–48.
- Peacock HM, De Gendt C, Silversmit G, et al. Stage shift and relative survival for head and neck cancer during the 2020 COVID-19 pandemic: a population-based study of temporal trends. Front Oncol. 2023; 13: 1253968.
- Piras A, Venuti V, D'Aviero A, et al. Covid-19 and radiotherapy: a systematic review after 2 years of pandemic. Clin Transl Imaging. 2022; 10(6): 611–630.
- Szewczyk M, Pazdrowski J, Golusiński P, et al. The impact of the COVID-19 pandemic on the management of head and neck cancer patients at a tertiary care institution in Poland. Contemp Oncol (Pozn). 2021; 25(4): 264–269.
- Heckel S, Bohr C, Meier J, et al. Head and neck oncology management in the time of COVID-19: results of a head and neck cancer center. J Cancer Res Clin Oncol. 2023; 149(13): 12081–12087.
- Cwinthal M, Shih H, Idrissi Janati A, et al. The effect of the COVID-19 pandemic on the diagnosis and progression of oral cancer. Int J Oral Maxillofac Surg. 2024; 53(8): 629–634.
- Johnson S, Corsten MJ, McDonald JT, et al. Socio-economic factors and stage at presentation of head and neck cancer patients in Ottawa, Canada: a logistic regression analysis. Oral Oncol. 2010; 46(5): 366–368.
- Ireland National Cancer Registry. COVID-19 Impact on cancer incidence in Ireland in 2021. https://www.ncri.ie/publications/statistical-reports.
- Ireland The Citizens Assembly. Report of the Citizens’ Assembly on Gender Equality. 2021. https://citizensassembly.ie/overview-previous-assemblies/assembly-on-gender-equality/report/.
- Cascini F, Failla G, Gobbi C, et al. A cross-country comparison of Covid-19 containment measures and their effects on the epidemic curves. BMC Public Health. 2022; 22(1): 1765.